Logo

Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)

Share this

Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)

Shots:

  • The P-III A4091059 study involves assessing of tanezumab (5mg-10mg) vs PBO vs tramadol (prolonged release) in 1-832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in North America- EU and Asia for 56 wks.
  • The P-III A4091059 study results: well tolerated @56wks.; RPOA (1.4% vs 0.1%); ratio of RPOA type 1 (accelerated joint space narrowing) RPOA type 2 (damage or deterioration of the joint)- 6:1; Subchondral insufficiency fracture (0.4%); total joint replacement (0.7%); no events of osteonecrosis
  • Tanezumab (5mg- 10mg- SC) is a mAb- NGF inhibitor and has also received FDA’s FT designation in Jun-2017. In 2013- Pfizer and Lilly collaborated to jointly develop and commercialize tanezumab 

Ref: Pfizer | Image: Patient Daily

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions